Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | HTR2C | P28335 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 14/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4055137 | 0.84 | NR1H2 (0.56) | HTR2AHTR2CKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL23725782 | 0.80 | HTR2A (0.50) | HTR2AHTR2CSIGMAR1MEN1KMT2A | |
| SCHEMBL26683906 | 0.80 | SIGMAR1 (0.47) | SIGMAR1 | |
| SCHEMBL4049250 | 0.79 | HTR2A (0.59) | HTR2AHTR2CKDM4EALDH1A1HPGD | |
| SCHEMBL5380065 | 0.77 | SIGMAR1 (0.64) | SIGMAR1 | |
| SCHEMBL7888632 | 0.76 | HTR2A (0.53) | HTR2AHTR2CKDM4EALDH1A1HPGD | |
| SCHEMBL1104004 | 0.76 | HTR2A (0.53) | HTR2AHTR2CKDM4EALDH1A1HPGD | |
| SCHEMBL13743172 | 0.76 | HTR2C (0.56) | HTR2AHTR2CKDM4EALDH1A1HPGD | |
| Fumaric Acid SCHEMBL16197823 | 0.74 | KEAP1 (0.46) | HTR2AHTR2CKDM4EALDH1A1SMN1; SMN2 | |
| Fumaric Acid SCHEMBL16197824 | 0.74 | KEAP1 (0.46) | HTR2AHTR2CKDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009097515-A2 | [A]-FUSED INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-08-06 | — | — | WO | disclosed |
| US-20090192147-A1 | [a]-FUSED INDOLE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192147-A1 | [a]-FUSED INDOLE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | MTOR, RICTOR, PIK3C2A | HTR2A 780/4885HTR2C 826/4885KDM4E 1263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.